Glofitamab induces durable complete remissions in patients with relapsed large B-cell lymphoma

Glofitamab induces durable complete remissions in patients with relapsed large B-cell lymphoma

Update on Phase I/II study of glofitamab monotherapy in R/R MCLПодробнее

Update on Phase I/II study of glofitamab monotherapy in R/R MCL

Insights into Phase I/II study assessing fixed-duration glofitamab treatment for R/R LBCLПодробнее

Insights into Phase I/II study assessing fixed-duration glofitamab treatment for R/R LBCL

Phase II study of glofitamab in patients with R/R LBCLПодробнее

Phase II study of glofitamab in patients with R/R LBCL

COALITION: glofitamab + R-CHOP or glofitamab + pola-R-CHP in high-risk DLBCLПодробнее

COALITION: glofitamab + R-CHOP or glofitamab + pola-R-CHP in high-risk DLBCL

What is the rationale behind the combination of glofitamab + polatuzumab in patients with R/R DLBCL?Подробнее

What is the rationale behind the combination of glofitamab + polatuzumab in patients with R/R DLBCL?

Glofitamab in R/R DLBCL: updated safety and efficacy dataПодробнее

Glofitamab in R/R DLBCL: updated safety and efficacy data

A Phase I/II trial of glofitamab monotherapy in R/R MCLПодробнее

A Phase I/II trial of glofitamab monotherapy in R/R MCL

Michael Dickinson, MBBS, DMedSc, on a Phase II Trial of Glofitamab in DLBCLПодробнее

Michael Dickinson, MBBS, DMedSc, on a Phase II Trial of Glofitamab in DLBCL

The current and future role of bispecifics in R/R DLBCL: epcoritamab, glofitamab & moreПодробнее

The current and future role of bispecifics in R/R DLBCL: epcoritamab, glofitamab & more

Updated results of glofitamab plus polatuzumab vedotin combination therapy in DLBCL, including HGBCLПодробнее

Updated results of glofitamab plus polatuzumab vedotin combination therapy in DLBCL, including HGBCL

Glofitamab: a valuable agent for the treatment of patients with R/R mantle cell lymphomaПодробнее

Glofitamab: a valuable agent for the treatment of patients with R/R mantle cell lymphoma

Glofitamab for Richter’s TransformationПодробнее

Glofitamab for Richter’s Transformation

ASH highlights: glofitamab in DLBCL & pirtobrutinib and epcoritamab in Richter's transformationПодробнее

ASH highlights: glofitamab in DLBCL & pirtobrutinib and epcoritamab in Richter's transformation

Relapsed and Refractory Diffuse Large B-Cell LymphomaПодробнее

Relapsed and Refractory Diffuse Large B-Cell Lymphoma

The emerging potential of bispecific antibodies as monotherapy & in combination for B-cell lymphomaПодробнее

The emerging potential of bispecific antibodies as monotherapy & in combination for B-cell lymphoma

Glofitamab as a SOC in third-line DLBCL and its potential in earlier lines of therapyПодробнее

Glofitamab as a SOC in third-line DLBCL and its potential in earlier lines of therapy

The benefits of glofitamab in R/R DLBCL post-CAR-T therapyПодробнее

The benefits of glofitamab in R/R DLBCL post-CAR-T therapy

Follow-up results of EPCORE NHL-1: subcutaneous epcoritamab in R/R LBCLПодробнее

Follow-up results of EPCORE NHL-1: subcutaneous epcoritamab in R/R LBCL

The STARGLO trial: glofitamab in combination with gemcitabine and oxaliplatin in R/R DLBCLПодробнее

The STARGLO trial: glofitamab in combination with gemcitabine and oxaliplatin in R/R DLBCL